Minerva Neurosciences, Inc. (NASDAQ:NERV – Get Free Report) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 7,200 shares, a drop of 25.0% from the September 30th total of 9,600 shares. Based on an average trading volume of 16,400 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the shares of the stock are short sold.
Minerva Neurosciences Stock Performance
Minerva Neurosciences stock traded down $0.02 during mid-day trading on Friday, reaching $2.44. The stock had a trading volume of 9,113 shares, compared to its average volume of 54,820. The stock’s 50-day simple moving average is $2.68 and its 200-day simple moving average is $2.80. Minerva Neurosciences has a fifty-two week low of $2.26 and a fifty-two week high of $13.49. The firm has a market capitalization of $17.05 million, a PE ratio of -0.55 and a beta of 0.14.
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). On average, research analysts forecast that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Stock Analysis on Minerva Neurosciences
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
See Also
- Five stocks we like better than Minerva Neurosciences
- What Is WallStreetBets and What Stocks Are They Targeting?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What Are the U.K. Market Holidays? How to Invest and Trade
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Comparing and Trading High PE Ratio Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.